

Tissue Regenix Group plc
('Tissue Regenix', the 'Group', or the 'Company')

**Result of General Meeting
and
Cancellation**

Tissue Regenix Group plc (AIM: TRX), the regenerative medical devices company, announces that at the General Meeting ('General Meeting') held earlier today, all resolutions were duly passed on a show of hands.

The results of the proxy votes received in respect of the resolutions, given to the Chair prior to the meeting, are set out below:

Resolution		In favour	%	Against	%	Withheld
1	Ordinary	18,821,081	65.4	9,979,283	34.6	20,362,691
2	Ordinary	34,592,438	77.4	10,099,500	22.6	4,471,117
3	Special	34,652,075	77.5	10,038,289	22.5	4,472,691
4	Special	34,463,372	77.1	10,243,999	22.9	4,455,684
5	Special	34,479,402	77.1	10,229,337	22.9	4,454,316
6	Special	34,460,155	77.1	10,226,292	22.9	4,476,608

Notes:

1. A "Vote withheld" is not counted in the calculation of the percentage of shares voted "In favour" or "Against".
2. As at 18 December 2025, being the voting deadline date in respect of the General Meeting, the total number of Ordinary Shares of 0.1p each in issue and the total number of voting rights was 71,395,635.

The full text of the resolutions passed at the General Meeting may be found in the Notice of General Meeting section within the circular published and sent to shareholders on 4 December 2025 ("the Circular").

The initial £7.5m of Secured Convertible Loan Notes from Harwood will therefore now be issued by the Company. Following the drawdown of the £7.5m, the Company expects to be able to restore payments to creditors whilst the new senior management look to stabilise the business and execute their recovery plan to return the Company to profitability.

Cancellation

Further to the passing of Resolution 4, in accordance with Rule 41 of the AIM Rules for Companies, the last day of admission of the Company's Ordinary Shares to trading on AIM will be 6 January 2026, and cancellation of the admission of the Company's Ordinary Shares to trading on AIM will become effective on 7 January 2026. Following the Cancellation, the Company will re-register as a private limited company and adopt new articles of association, as detailed within the Circular.

The Company intends to provide a secondary market trading facility through Asset Match, to enable Shareholders to trade in the shares on a periodic basis. This facility will commence on 7 January 2026, following Cancellation becoming effective. Further details on how to participate in the secondary market trading facility via Asset Match are included within the Circular.

Commenting, Jay LeCoque, Executive Chairman, said: "I would like to thank all of the shareholders who have voted in support of the resolutions, which was essential for Tissue Regenix to continue as a viable business, and provides the funding required to take full commercial advantage of our leading products and superior technology. In particular, I would like to thank the team at Harwood Private Equity, for providing significant financial security for the business when no other options were available. Securing funding at this scale and within such a tight frame was a remarkable achievement and I am very grateful to everyone who has helped to make this happen.

"The business has excellent proprietary technology, a strong commercial proposition, and a highly talented and dedicated group of employees, and so I am delighted for the Tissue Regenix team, for our shareholders and for the patients who will benefit from our technology, that our path forward is now secured."

Defined terms not otherwise defined within this announcement have the same meaning as given in the announcement published by the Company on 4 December 2025.

For more information, please contact:

Tissue Regenix Group plc
Jay LeCoque, Executive Chairman

via Walbrook PR

Cavendish Capital Markets (Nominated Adviser and Broker)
Genf Nash/Edward White/Hamza Munshi

Tel: +44 (0) 20 7466 5000

Walbrook PR (Financial PR and IR)
Alice Woodings / Paul McManus

Tel: +44 (0)20 7933 8780 or TissueRegenix@walbrookpr.com
Mob: +44 (0)7407 804 654 / +44 (0)7980 541 893

About Tissue Regenix (www.tissueregenix.com)

Tissue Regenix is a leading medical device company in regenerative medicine. The Company's patented decellularisation technology (dCELL®) removes DNA and other cellular material from animal and human soft tissue, leaving an acellular tissue scaffold that is not rejected by the patient's body and can be used to repair diseased or damaged body structures. Current applications address many crucial clinical needs in sports medicine, foot and ankle injuries, and wound care.

In August 2017, Tissue Regenix acquired CellRight Technologies®. This biotech company specialises in regenerative medicine and is dedicated to developing high-quality, innovative tissue scaffolds to enhance healing opportunities in defects created by trauma and disease. CellRight's human tissue products may be used in spine, trauma, general orthopaedic, dental and ophthalmological surgical procedures.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

ROMPKBBKABDDABB